方法对比
并排查看您选择的方法；存在差异的行会高亮显示。
| MTT/MTS 测定法× | 溶血试验× | |
|---|---|---|
| 领域 | 生物材料 | 生物材料 |
| 方法族 | Process / pipeline | Process / pipeline |
| 起源年份≠ | 1983 | 1950 |
| 提出者≠ | Tatsuro Mosmann | Clinical hematology traditions |
| 类型≠ | Colorimetric assay | Hemolytic compatibility assay |
| 开创性文献≠ | Mosmann, T. (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. Journal of Immunological Methods, 65(1-2), 55-63. DOI ↗ | ASTM F756-17 (2017). Standard Practice for Assessment of Hemolytic Properties of Materials. ASTM International. link ↗ |
| 别名 | 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, tetrazolium assay, mitochondrial activity assay | RBC lysis assay, hemolytic compatibility test, hemolytic potential test |
| 相关 | 4 | 4 |
| 摘要≠ | The MTT assay, introduced by Tatsuro Mosmann in 1983, is a colorimetric method for quantifying cell viability and proliferation by measuring mitochondrial metabolic activity. The method detects the conversion of the water-soluble tetrazolium salt MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) by active mitochondria, producing an insoluble purple formazan precipitate proportional to the number of viable cells. The related MTS assay, which does not require solubilization, offers improved kinetics and is now widely adopted in both academic research and pharmaceutical development. | The hemolysis assay is a standard method for evaluating the blood compatibility of biomaterials by quantifying the extent to which a material or substance damages red blood cells (RBCs) and causes hemoglobin release. Codified in standards including ASTM F756 and ISO 10993-4, the hemolysis assay is essential for regulatory approval of blood-contacting devices such as stents, catheters, artificial heart valves, and hemodialysis membranes. The assay provides a simple, quantitative measure of hemolytic potential that correlates with clinical safety. |
| ScholarGate数据集 ↗ |
|
|